Extended-release naltrexone initiated after just five to seven days of seeking treatment is more effective than starting treatment after the traditional interim stage of 10 to 15 days.
Columbia psychologist Erin K. Engle discusses the signs that indicate the time is right to stop therapy and questions patients should ask themselves before moving on.
A mood-stabilizing drug prescribed to many patients with schizophrenia or bipolar disorder may decrease negative symptoms for people with a certain variant of the COMT gene.
An international observational study led by Columbia University researchers has uncovered widespread differences in the treatment of patients with common chronic diseases, including type 2 diabetes, hypertension, and depression.